UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

BMC rheumatology, 2018-01, Vol.2 (1), p.23-23, Article 23

2018

Volltextzugriff (PDF)

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

Clinical pharmacokinetics, 2016-12, Vol.55 (12), p.1547-1558

2016

Volltextzugriff (PDF)

Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure

JACC. Heart failure, 2013-04, Vol.1 (2), p.103-111

2013

Volltextzugriff (PDF)

ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study

Arthritis & rheumatology (Hoboken, N.J.), 2018-11, Vol.70 (11), p.1710-1720

2018

Volltextzugriff (PDF)

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

JAMA : the journal of the American Medical Association, 2007-05, Vol.297 (17), p.1883

2007

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacodynamics of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2017-12, Vol.69 (12), p.2283-2291

2017

Volltextzugriff (PDF)

A Causal Role for Endothelin-1 in the Pathogenesis of Osteoblastic Bone Metastases

Proceedings of the National Academy of Sciences - PNAS, 2003-09, Vol.100 (19), p.10954-10959

2003

Volltextzugriff (PDF)

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

Journal of clinical oncology, 2003-02, Vol.21 (4), p.679-689

2003

Volltextzugriff (PDF)

Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β-blockers in SURVIVE

European journal of heart failure, 2009-03, Vol.11 (3), p.304-311

2009

Volltextzugriff (PDF)

Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study

The International Journal of Cardiovascular Imaging, 2015-01, Vol.31 (1), p.95-103

2015

Volltextzugriff (PDF)

ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Arthritis & rheumatology (Hoboken, N.J.), 2018-11, Vol.70 (11), p.1710-1720

2018

Volltextzugriff (PDF)

Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: Data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial

Critical care medicine, 2011-05, Vol.39 (5), p.940-944

2011

Volltextzugriff (PDF)

Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcome (AIM―HIGH) Trial

Stroke (1970), 2013-10, Vol.44 (10), p.2688-2693

2013

Volltextzugriff (PDF)

The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

The New England journal of medicine, 1996-08, Vol.335 (8), p.533-540

1996

Volltextzugriff (PDF)

Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics

Journal of clinical oncology, 2002-04, Vol.20 (8), p.2171-2180

2002

Volltextzugriff (PDF)

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy

Vascular health and risk management, 2012-01, Vol.8 (default), p.39-44

2012

Volltextzugriff (PDF)

Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study

The European journal of health economics, 2010-04, Vol.11 (2), p.185-193

2010

Volltextzugriff (PDF)

Important Considerations for Treatment with Dietary Supplement versus Prescription Niacin Products

Postgraduate medicine, 2011-03, Vol.123 (2), p.70-83

2011

Volltextzugriff (PDF)

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

Urology (Ridgewood, N.J.), 2001-11, Vol.58 (5), p.717-722

2001

Volltextzugriff (PDF)

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

Vascular health and risk management, 2010-01, Vol.6 (default), p.1065-1075

2010

Volltextzugriff (PDF)

Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study

Journal of clinical lipidology, 2009-04, Vol.3 (2), p.109-118

2009

Volltextzugriff (PDF)

Flushing ASsessment Tool (FAST©): Psychometric Properties of a New Measure Assessing Flushing Symptoms and Clinical Impact of Niacin Therapy

Clinical drug investigation, 2009-01, Vol.29 (4), p.215-229

2009

Volltextzugriff (PDF)

ABT-627, an endothelin ET A receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain

European journal of pharmacology, 2000-01, Vol.388 (1), p.29-35

2000

Volltextzugriff (PDF)

Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009-03, Vol.9 (2), p.69-79

2009

Volltextzugriff (PDF)

Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events: A Pooled Analysis

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011-06, Vol.11 (3), p.179-187

2011

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(89)
Berichte
(1)

Sprache

Englisch
(90)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure

ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

Safety, Tolerability, and Pharmacodynamics of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis

A Causal Role for Endothelin-1 in the Pathogenesis of Osteoblastic Bone Metastases

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β-blockers in SURVIVE

Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study

ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: Data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial

Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcome (AIM―HIGH) Trial

The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy

Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study

Important Considerations for Treatment with Dietary Supplement versus Prescription Niacin Products

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study

Flushing ASsessment Tool (FAST©): Psychometric Properties of a New Measure Assessing Flushing Symptoms and Clinical Impact of Niacin Therapy

ABT-627, an endothelin ET A receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain

Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia

Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events: A Pooled Analysis

Suchergebnisse filtern